Considering early detection of relapsed ovarian cancer : A review of the literature

International Journal of Gynecological Cancer

Volumn 21, Issue 5, 2011, Pages 837-845

  Geurts, Sandra M E ^a,b   De Vegt, Femmie ^a   Van Altena, Anne M ^b   Van Dijck, Jos A A M ^a   Tjan Heijnen, Vivianne C G ^c   Verbeek, André L M ^a   Massuger, Leon F A G ^b  

^a Medical Centre   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lead time; Ovarian cancer; Routine follow up; Systematic review

Indexed keywords

CA 125 ANTIGEN;

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; EARLY DIAGNOSIS; EMBASE; EVALUATION AND FOLLOW UP; HUMAN; MEDLINE; OVARY CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 82955161529     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821bb88c     Document Type: Review

References (23)

1. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v23-v30.
2. Health Council of the Netherlands. Follow-up in Oncology: Identify Objectives, Substantiate Actions. Report No. 2007/10. The Hague, The Netherlands: Health Council of the Netherlands; 2007.
3. Kew FM, Galaal K, Manderville H. Patients' views of follow-up after treatment for gynaecological cancer. J Obstet Gynaecol. 2009;29:135-142.
4. Rustin GJS, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer(MRCOV05/EORTC 55955): A randomised trial. Lancet. 2010;376:1155-1163.
5. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.
6. Rustin GJS, van der Burg MEL, et al. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA 125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol. 2009;27:A1.
7. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19:367-374.
8. Chan KKL, Tam KF, Tse KY, et al. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol. 2008;110:158-161.
9. Von Georgi R, Schubert K, Grant P, et al. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2004;114:228-233. (Pubitemid 38622087)
10. Taylor P Jr, Orr JW Jr, Dark I, et al. Advanced epithelial ovarian cancer: Clinical patterns of relapse following complete response to initial treatment: A prospective comparison of methods of surveillance. Gynecol Oncol. 2006;101:S88.
11. Menczer J, Chetrit A, Sadetzki S, et al. Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol. 2006;103:137-140. (Pubitemid 44389865)
12. Nordin AJ. Mode of detection of recurrent gynecological malignancy: Does routine follow-up delay diagnosis and treatment? Int J Gynecol Cancer. 2006;16:1746-1748. (Pubitemid 44470030)
13. Fehm T, Heller F, Krämer S, et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25:1551-1554. (Pubitemid 40896763)
14. Olaitan A, Murdoch J, Anderson R, et al. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: A pilot study. Int J Gynecol Cancer. 2001;11:349-353. (Pubitemid 33021135)
15. Gu P, Pan LL,Wu SQ, et al. CA 125, PETalone, PET-CT, CTand MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis. Eur J Radiol. 2009;71:164-174.
16. Ovarian Cancer National Alliance (www.ovariancancer.org) and SEER Cancer Statistics Review. StatBite: Ovarian cancer: Risk of recurrence by stage of diagnosis. J Natl Cancer Inst. 2009;101:1234.
17. Fitch MI, Steele R. Identifying supportive care needs of women with ovarian cancer. Can Oncol Nurs J. 2010;20:66-74.
18. Corner J. The role of nurse-led care in cancer management. Lancet Oncol. 2003;4:631-636. (Pubitemid 37258405)
19. Moses SH, Olaitan A, Murdoch JB, et al. A pilot randomised controlled study of three models of follow-up of patients treated for gynaecological cancer: Attitudes in general practice and feasibility of randomisation. J Obstet Gynaecol. 2004;24:165-166. (Pubitemid 38234078)
20. Del Giudice ME, Grunfeld E, Harvey BJ, et al. Primary care physicians' views of routine follow-up care of cancer survivors. J Clin Oncol. 2009;27:3338-3345.
21. Kew FM, Cruickshank DJ, Russell IT, et al. FIGURE: Follow-up in gynae oncology units, randomised evaluationVa feasibility study. Int J Gynecol Cancer. 2004;14:S153.
22. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol. 2009;112:265-274.
23. Harter P, Hilpert F, Mahner S, et al. Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer. 2009;19:S14-S17.